SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001104659-18-067019
Filing Date
2018-11-08
Accepted
2018-11-08 17:01:42
Documents
2
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13D a18-39824_1sc13d.htm SC 13D 183673
2 EX-1 a18-39824_1ex1.htm EX-1 19664
  Complete submission text file 0001104659-18-067019.txt   204803
Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8
Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474
NOVARTIS PHARMA AG (Filed by) CIK: 0001030617 (see all company filings)

Type: SC 13D

Mailing Address 5 NAHUM HAFZADI STREET JERUSALEM L3 95484
Business Address 5 NAHUM HAFZADI STREET JERUSALEM L3 95484 97226595666
Gamida Cell Ltd. (Subject) CIK: 0001600847 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90706 | Film No.: 181170460
SIC: 2836 Biological Products, (No Diagnostic Substances)